You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tumor growth inhibitor (TGI)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

OPTImal PALliative Anti-epidermal Growth Factor Receptor

Active, not recruiting
  • Colorectal Cancer Metastatic
  • +5 more
  • Plasma circulating DNA analysis
  • Aarhus, Denmark
    Aarhus University Hospital
Feb 24, 2022

NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)

Recruiting
  • NSCLC Stage IV
  • Taipei, Taiwan
  • +1 more
Mar 8, 2022

NSCLC Trial in Seoul (BBT-176, Cetuximab)

Recruiting
  • NSCLC
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +3 more
Jan 6, 2023

Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

Completed
Has Results
  • Lymphoma, Large-Cell, Anaplastic
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 26, 2021

Malignant Solid Tumor Trial in Grand Rapids, Houston, Toronto (AVID200)

Unknown status
  • Malignant Solid Tumor
  • Grand Rapids, Michigan
  • +2 more
Dec 17, 2020

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +3 more
  • New Haven, Connecticut
  • +4 more
Jan 27, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Duarte, California
  • +14 more
Jan 27, 2023

Solid Tumor Trial in Busan, Daegu, Seoul (ISU104, Cetuximab)

Active, not recruiting
  • Solid Tumor
  • Busan, Korea, Republic of
  • +4 more
May 3, 2021

Adult Solid Tumor Trial in Rochester (Erlotinib Hydrochloride, Irinotecan Hydrochloride)

Active, not recruiting
  • Adult Solid Neoplasm
  • Erlotinib Hydrochloride
  • Irinotecan Hydrochloride
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 25, 2023

Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)

Recruiting
  • Breast Cancer
  • ER Positive Breast Cancer
  • Letrozole 2.5mg
  • Lebanon, New Hampshire
  • +1 more
Dec 19, 2022

Ovarian Cancer, Breast Cancer, Solid Tumor Trial in Houston, Brisbane (CYH33)

Recruiting
  • Ovarian Cancer
  • +4 more
  • New Haven, Connecticut
  • +6 more
Oct 10, 2022

Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma Trial in United States

Completed
  • Fallopian Tube Carcinoma
  • +37 more
  • Bevacizumab
  • +5 more
  • Birmingham, Alabama
  • +22 more
Oct 19, 2021

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Brain and CNS Tumors Trial in United States (BGB 324 (before surgery), BGB 324 (after surgery))

Active, not recruiting
  • Brain and Central Nervous System Tumors
  • BGB 324 (before surgery)
  • BGB 324 (after surgery)
  • Birmingham, Alabama
  • +5 more
Dec 1, 2022

Stage II Renal Cell Cancer, Stage III Renal Cell Cancer Trial (tivozanib, therapeutic conventional surgery)

Withdrawn
  • Stage II Renal Cell Cancer
  • Stage III Renal Cell Cancer
  • (no location specified)
Aug 11, 2022

Oral Carcinoma Trial in Beijing (68Ga-FAPI-04)

Recruiting
  • Oral Carcinoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Oct 26, 2022

Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma Trial in Spain (Cabozantinib 40 mg)

Recruiting
  • Neuroendocrine Tumor
  • +4 more
  • Cabozantinib 40 mg
  • Badalona, Barcelona, Spain
  • +14 more
Feb 15, 2022

Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer Trial in Buffalo (dovitinib lactate,

Completed
  • Adenocarcinoma of the Pancreas
  • +3 more
  • dovitinib lactate
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2022

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Recurrent NSCLC Trial in Sacramento, San Francisco (INC280, erlotinib HCl)

Completed
  • Recurrent Non-small Cell Lung Cancer
  • Sacramento, California
  • +1 more
Oct 11, 2021

Anlotinib Treatment Response Using Contrast Enhanced Ultrasound

Recruiting
  • Pheochromocytoma, Metastatic
  • +3 more
  • Contrast-enhanced ultrasound(CEUS)
  • Beijing, China
    Peking Union Medical College Hospital
Aug 28, 2023

Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation Trial in United States (Vismodegib, FAK Inhibitor GSK2256098,

Recruiting
  • Intracranial Meningioma
  • +2 more
  • Birmingham, Alabama
  • +707 more
Sep 25, 2022